{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:41:28Z","timestamp":1785894088607,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40262-019-00739-3","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T04:42:14Z","timestamp":1554352934000},"page":"1045-1058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I\u2013III Clinical Trials"],"prefix":"10.1007","volume":"58","author":[{"given":"Ben","family":"Kl\u00fcnder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendar K.","family":"Mittapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Friedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Noertersheuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-2775","authenticated-orcid":false,"given":"Ahmed A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"739_CR1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094\u2013108.","journal-title":"Lancet"},{"key":"739_CR2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud CJ. The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018;10:117\u201327.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"739_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF02981951","volume":"73","author":"WJ Leonard","year":"2001","unstructured":"Leonard WJ. Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol. 2001;73:271\u20137.","journal-title":"Int J Hematol"},{"key":"739_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","volume":"36","author":"JJ O\u2019Shea","year":"2012","unstructured":"O\u2019Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012;36:542\u201350.","journal-title":"Immunity"},{"key":"739_CR5","first-page":"1","volume":"65","author":"J Voss","year":"2013","unstructured":"Voss J, Graff C, Schwartz A, Hyland D, Argiriadi M, Camp H, et al. Pharmacodynamics of a novel Jak1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects. Arthritis Rheum. 2013;65:1.","journal-title":"Arthritis Rheum"},{"key":"739_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234\u201343.","journal-title":"Nat Rev Rheumatol"},{"key":"739_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.coph.2012.06.008","volume":"12","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, Kotlyar A, Laurence A, Changelian P, O\u2019Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol. 2012;12:464\u201370.","journal-title":"Curr Opin Pharmacol"},{"key":"739_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","volume":"93","author":"H Neubauer","year":"1998","unstructured":"Neubauer H, Cumano A, M\u00fcller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397\u2013409.","journal-title":"Cell"},{"key":"739_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/13543784.2014.918604","volume":"23","author":"P Norman","year":"2014","unstructured":"Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23:1067\u201377.","journal-title":"Expert Opin Investig Drugs"},{"key":"739_CR10","doi-asserted-by":"crossref","unstructured":"Mohamed M-EF, Camp HS, Jiang P, Padley RJ, Asatryan A, Othman AA. Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis. Clin Pharmacokinet. 2016;55:1547\u201358.","DOI":"10.1007\/s40262-016-0419-y"},{"key":"739_CR11","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/art.39808","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2016;68:2857\u201366.","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"739_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/cpdd.462","volume":"8","author":"M-EF Mohamed","year":"2019","unstructured":"Mohamed M-EF, Zeng J, Marroum PJ, Song I-H, Othman AA. Pharmacokinetics of upadacitinib with the clinical regimens of the extended-release formulation utilized in rheumatoid arthritis phase 3 trials. Clin Pharmacol Drug Dev. 2019;8(2):208\u201316. \n                    https:\/\/doi.org\/10.1002\/cpdd.462\n                    \n                  .","journal-title":"Clin Pharmacol Drug Dev."},{"key":"739_CR13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"739_CR14","doi-asserted-by":"crossref","unstructured":"Kl\u00fcnder B, Mohamed M-EF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018;57:977\u201388.","DOI":"10.1007\/s40262-017-0605-6"},{"key":"739_CR15","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/art.39801","volume":"68","author":"JM Kremer","year":"2016","unstructured":"Kremer JM, Emery P, Camp HS, Friedman A, Wang L, Othman AA, et al. A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Arthritis Rheumatol. 2016;68:2867\u201377.","journal-title":"Arthritis Rheumatol."},{"key":"739_CR16","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"739_CR17","unstructured":"Roy F. A phase 3, randomized, double-blind study comparing upadacitinib to placebo and to adalimumab, in patients with active rheumatoid arthritis with inadequate response to methotrexate [abstract no. 72780]. American College of Rheumatology Meeting Abstracts; 2018."},{"key":"739_CR18","doi-asserted-by":"crossref","unstructured":"van Vollenhoven R. A phase 3, randomized, controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-na\u00efve patients with active rheumatoid arthritis [abstract no. 75147]. American College of Rheumatology Meeting Abstracts; 2018.","DOI":"10.1093\/rheumatology\/kez106.058"},{"key":"739_CR19","doi-asserted-by":"crossref","unstructured":"Smolen JS. Upadacitinib As Monotherapy: A phase 3 randomized controlled double- blind study in patients with active rheumatoid arthritis and inadequate response to methotrexate. American College of Rheumatology Meeting Abstracts; 2018.","DOI":"10.1093\/rheumatology\/kez106.059"},{"key":"739_CR20","doi-asserted-by":"crossref","unstructured":"Tanaka Y. A Phase2b\/3 randomized, placebo-controlled, double-blind study of upadacitinib, a selective JAK1 inhibitor, in Japanese patients with active rheumatoid arthritis and inadequate response to conventional synthetic dmards. EULAR18-4302. European League Against Rheumatism; 2018.","DOI":"10.1136\/annrheumdis-2018-eular.4302"},{"key":"739_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"739_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev.pa.32.040192.001153","volume":"32","author":"LB Sheiner","year":"1992","unstructured":"Sheiner LB, Ludden TM. Population pharmacokinetics\/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185\u2013209.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"739_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351.","journal-title":"AAPS J"},{"key":"739_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","volume":"54","author":"F Namour","year":"2015","unstructured":"Namour F, Diderichsen PM, Cox E, Vayssi\u00e8re B, Van der Aa A, Tasset C, et al. Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54:859\u201374.","journal-title":"Clin Pharmacokinet"},{"key":"739_CR25","volume-title":"Clinical pharmacology and biopharmaceutics review(s)\u2014tofacitinib","author":"FDA Us","year":"2011","unstructured":"Us FDA. Clinical pharmacology and biopharmaceutics review(s)\u2014tofacitinib. Silver Spring: Center for Drug Evaluation and Research, US FDA; 2011."},{"key":"739_CR26","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1096\/fj.02-0195fje","volume":"16","author":"R Jover","year":"2002","unstructured":"Jover R, Bort R, G\u00f3mez-Lech\u00f3n MJ, Castell JV. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 2002;16:1799\u2013801.","journal-title":"FASEB J."},{"key":"739_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1375","author":"M-EF Mohamed","year":"2002","unstructured":"Mohamed M-EF, Coppola S, Feng T, Anderson J, Othman AA. Characterization of the effect of renal impairment on upadacitinib pharmacokinetics. J Clin Pharmacol. \n                    https:\/\/doi.org\/10.1002\/jcph.1375\n                    \n                  .","journal-title":"J Clin Pharmacol."},{"key":"739_CR28","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1111\/bcp.13329","volume":"83","author":"M-EF Mohamed","year":"2002","unstructured":"Mohamed M-EF, Jungerwirth S, Asatryan A, Jiang P, Othman AA. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83:2242\u20138.","journal-title":"Br J Clin Pharmacol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00739-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T23:09:27Z","timestamp":1585782567000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00739-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["739"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00739-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"3 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The studies were designed according to good clinical practice guidelines, the Declaration of Helsinki, and applicable regulations, and were approved by Institutional Review Boards. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Informed Consent"}},{"value":"This study was sponsored by AbbVie Inc., who contributed to the study design; research; data interpretation; and writing, review and approval of the abstract for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ben Kl\u00fcnder, Rajendar K. Mittapalli, Mohamed-Eslam F. Mohamed, Anna Friedel, Peter Noertersheuser and Ahmed A. Othman are employees or former employees of AbbVie Inc., and may hold AbbVie stocks or options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis datasets), as well as other information (e.g. protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.The clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12\u00a0months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: .","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}}]}}